Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-κB inhibitor DHMEQ

Current Pharmaceutical Design

Volumn 15, Issue 7, 2009, Pages 792-808

  Katsman, Alina ^a   Umezawa, Kazuo ^b   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Chemo immuno sensitization; DHMEQ; Immunosurveillance cancer gene RKIP; Metastasis; NF B inhibition; Overcoming resistance; Regulation of apoptotic pathways; Snail

Indexed keywords

CH 11; DEHYDROXYMETHYLEPOXYQUINOMICIN; FAS LIGAND; FLUDARABINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BCL 2; RITUXIMAB; SALINOSPORAMIDE A; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMOSENSITIZATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DRUG DNA BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIZATION; DRUG STRUCTURE; EPITHELIAL CELL TO MESENCHYMAL CELL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; METASTASIS; METASTASIS INHIBITION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TUMOR IMMUNITY; UPREGULATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CYCLOHEXANONES; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NF-KAPPA B;

EID: 64549164046     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582156     Document Type: Review

References (103)

1. Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung 2008; 58: 261-4.
2. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-92.
3. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14(Suppl 1): 35-48.
4. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: From bench to bedside. Exp Biol Med (Maywood) 2008; 233: 21-31.
5. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076-82.
6. Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? J Cell Biochem 1994; 56: 37-47.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
8. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
9. MacKenzie SH, Clark AC. Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets 2008; 8: 98-109.
10. Wu AA, Niparko KJ, Pai SI. Immunotherapy for head and neck cancer. J Biomed Sci 2008; 15: 275-89.
11. Kipp RT, McNeel DG. Immunotherapy for prostate cancer - recent progress in clinical trials. Clin Adv Hematol Oncol 2007; 5: 465-74, 477-9.
12. Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: Two complementary signals to overcome cross-resistance. Adv Cancer Res 2002; 85: 145-174.
13. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007; 12: 1084-95.
14. Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008; 8(5): 523-32.
15. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629-36.
16. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-8.
17. Karin M. Nature. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
18. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: Balancing life and death - a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32.
19. Ghosh S, Karin M. Cell. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109(Suppl): S81-96.
20. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-7.
21. Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol 2006; 6: 111-30.
22. Karin M, Delhase M Semin. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signaling. Immunology 2000; 12: 85-98.
23. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
24. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gélinas C, et al. Regulation of death receptor expression and TRAIL/ Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3: 409-16.
25. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: Apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18: 7719-30.
26. Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
27. Boujrad H, Gubkina O, Robert N, Krantic S, Susin SA. AIF-mediated programmed necrosis: A highly regulated way to die. Cell Cycle 2007; 6: 2612-9.
28. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
29. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-47.
30. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64.
31. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33: 407-20.
32. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005; 64: 224-39.
33. Adams JM, Cory S. Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488-96.
34. Shabbits JA, Hu Y, Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther 2003; 2: 805-13.
35. Del Poeta G, Bruno A, Del Principe MI, Venditti A, Maurillo L, Buccisano F, et al. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets 2008; 8: 207-22.
36. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-6.
37. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961-82.
38. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-90
39. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20: 5865-77.
40. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Canc Netw 2006; 4: 687-94.
41. Srinivasan R, Van Epps DE. Specific active immunotherapy of cancer: potential and perspectives. Rev Recent Clin Trials 2006; 1: 283-92.
42. Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood 1996; 88: 1375-82.
43. Huerta-Yepez S, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol 2006; 120: 297-309.
44. Rothstein TL. Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res 2000; 10: 245-66.
45. Cretney E, Takeda K, Smyth MJ. Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007; 39: 280-6.
46. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
47. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19: 2195-202.
48. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008; 180: 6199-210.
49. Peták I, Houghton JA. Shared pathways: Death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001; 7: 95-106
50. Bonavida B. Overcoming cancer drug resistance: Two signal hit model in cell signaling for apoptosis by combination of sensitizing agents and chemotherapy. In: Bonavida B, Ed. Chemoxand immuno-sensitization of resistant tumor cells to cell death by apoptosis: Transworld Research Network 2006.
51. Ravi R, Bedi A. NF-kappaB in cancer--a friend turned foe. Drug Resist Updat 2004; 7: 53-67.
52. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 1999; 18: 6896-909.
53. Nam NH. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 2006; 6: 945-51.
54. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008; 15: 391-9.
55. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, et al. Synthesis of NF-kB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10: 865-9.
56. Zuzuki Y, Sugiyama C, Ohno O, Umezawa K. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-kB inhibitor. Tetrahedron 2004; 60: 7061-6.
57. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625-30
58. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 193-209.
59. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, et al. Targeting of nuclear factor kappaB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005; 11: 1287-93.
60. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K. Inactivation of NF-kappaB components by covalent binding of (-)- dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008; 51: 5780-8.
61. Katsman A, Umezawa K, Bonavida B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat 2007; 10: 1-12.
62. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264-76.
63. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-43.
64. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004; 64: 7117-26.
65. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333-50.
66. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67: 1270-81.
67. Vega MI, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B. The NF-kB inhibitors (bortezomib and DHMEQ) sensitize rituximab-resistant AIDS-BNHL. Leukemia Lymphoma 2008; 49(10): 1982-94.
68. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K. Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide 2008; 19: 152-7.
69. Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, et al. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: Analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol 2006; 28: 923-30.
70. Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, et al. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head Neck 2006; 28: 158-65.
71. Horie R, Watanabe M, Okamura T, Taira M, Shoda M, Motoji T, et al. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 800-6.
72. Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, et al. DHMEQ, a novel NF-{kappa}B inhibitor, enhances anti-tumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 2008; 149: 5357-65.
73. Garbán HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: A pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 2001; 167: 75-81.
74. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6: 1387-99.
75. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005; 62: 165-86.
76. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-53.
77. Bonavida B, Vega MI. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resist Updat 2005; 8: 27-41.
78. Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Umezawa K, et al. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. Int J Oncol 2006; 28: 841-6.
79. Marshall HE, Stamler JS. Inhibition of NF-kappa B by Snitrosylation. Biochemistry 2001; 40: 1688-93.
80. van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JA, Johnson JP, et al. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994; 269: 6185-92.
81. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435: 29-34.
82. Novak U, Cocks BG, Hamilton JA. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 1991; 19: 3389-93.
83. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene 2004; 23: 8509-19.
84. Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-29.
85. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003; 5: 101-6.
86. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001; 7: 1267-78.
87. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278: 21113-23.
88. Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18: 1131-43.
89. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008; 27: 2243-8.
90. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002; 21: 3241-6.
91. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26: 7445-56
92. Keller ET, Fu Z, Yeung K, Brennan M. Raf kinase inhibitor protein: A prostate cancer metastasis suppressor gene. Cancer Lett 2004; 207: 131-7.
93. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: Structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004; 91: 169-200.
94. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003; 95: 878-89.
95. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006; 66: 248-56
96. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 2004; 279:1 7515-23.
97. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006; 16: 451-6.
98. Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J, et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. Clin Endocrinol Metab 2008; 93: 1211-6.
99. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004; 64: 5186-92.
100. Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 2008; 6: 917-28.
101. Matarrese P, Ciarlo L, Tinari A, Piacentini M, Malorni W. Xeno-cannibalism as an exacerbation of self-cannibalism: A possible fruitful survival strategy for cancer cells. Curr Pharm Des 2008; 14(3): 245-52.
102. Robertson JH, Iga AM, Sales KM, Winslet MC, Seifalian AM. Integrins: A method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 2008; 14(3): 296-305.
103. Vannini N, Pfeffer U, Lorusso G, Noonan DM, Albini A. Endothelial cell aging and apoptosis in prevention and disease: E-selectin expression and modulation as a model. Curr Pharm Des 2008; 14(3): 221-5.